Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites

Inclusion Criteria: * Written informed consent has been obtained from the subject prior to FS VH S/D administration * Female subjects \>= 19 years of age * Subjects with breast cancer scheduled to undergo lumpectomy of the breast and level I and II axillary lymphadenectomy with two separate incisions Exclusion Criteria: * Subjects with known hypersensitivity to aprotinin or other components of the product * Subjects with immunodeficiency * Subjects with increased red cell production (e.g., in hemolytic anemia) * Subjects with coagulation disorders shown by exceeding the normal range of any of following: prothrombin time (PT), Quick, activated partial thromboplastin time (aPTT), fibrinogen level, or thrombocytes. * Subjects having previously had axillary surgery * Subjects having undergone irradiation therapy to the axillary tissue * Subjects having ever received chemotherapy before the surgery